|
gptkbp:instanceOf
|
gptkb:drug
nonsteroidal antiandrogen
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:European_Union
gptkb:Japan
gptkb:United_States
1995
|
|
gptkbp:ATCCode
|
gptkb:L02BB03
|
|
gptkbp:bioavailability
|
almost complete
|
|
gptkbp:brand
|
Casodex
Calutide
Bicalutamid
|
|
gptkbp:CASNumber
|
90357-06-5
|
|
gptkbp:chemicalFormula
|
C18H14F4N2O4S
|
|
gptkbp:contraindication
|
gptkb:women
children
pregnancy
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:drugClass
|
hormonal antineoplastic agent
antiandrogen
|
|
gptkbp:eliminationHalfLife
|
5–7 days
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasEnantiomer
|
(R)-bicalutamide
(S)-bicalutamide
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bicalutamide
|
|
gptkbp:KEGGID
|
D00294
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:mechanismOfAction
|
androgen receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
430.38 g/mol
|
|
gptkbp:pregnancyCategory
|
D
nan
X
X (contraindicated)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
2375
DB01128
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
liver toxicity
gynecomastia
hot flashes
sexual dysfunction
|
|
gptkbp:synonym
|
IUPAC: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
|
|
gptkbp:UNII
|
81X0L3H3BG
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:VESTANAT
|
|
gptkbp:bfsLayer
|
8
|